Has Jusmin Patel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $159,414 in general payments to Jusmin Patel, MD across 614 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jusmin Patel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jusmin Patel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jusmin Patel, MD

Nephrology · Reno, NVNPI 1518259647

Payments from drug & device makers

$159,414in general payments, 2019–2025

Across 614 payments — averaging $259.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim Pharma GmbH & Co.kg$44K
Travere Therapeutics, Inc.$27K
Hoffmann-la Roche Limited$25K
Boehringer Ingelheim$20K
Lilly USA, LLC$12K
Novartis$7K
plus $24K from 33 others

$215in research payments, 2019–2025

Across 1 payment — averaging $214.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$215

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim Pharma GmbH & Co.kg	37	$44,331
Travere Therapeutics, Inc.	42	$26,594
Hoffmann-la Roche Limited	6	$25,097
Boehringer Ingelheim	24	$19,916
Lilly USA, LLC	14	$12,236
Novartis	18	$7,376
Vifor Pharma, Inc.	32	$6,889
Boehringer Ingelheim International GmbH	10	$6,000
Eli Lilly	1	$3,500
Amgen(2 entities)	52	$1,249
OPKO Pharmaceuticals, LLC	116	$1,204
AstraZeneca(2 entities)	32	$934
Calliditas Therapeutics US Inc.	66	$742
Otsuka America Pharmaceutical, Inc.	43	$658
Bayer	29	$584
GSK	22	$483
ANI Pharmaceuticals, Inc.	11	$217
Aurinia Pharma U.S., Inc.	8	$177
Daiichi Sankyo Inc.	7	$146
Renalytix AI, Inc.	4	$137
Tactile Systems Technology Inc	3	$121
Mallinckrodt Hospital Products Inc.	5	$118
Takeda Pharmaceuticals U.S.A., Inc.	4	$101
Ardelyx, Inc.	4	$94
Mallinckrodt Enterprises LLC	1	$75
Fresenius USA Marketing, Inc.	3	$67
Akebia Therapeutics Inc	4	$55
Regeneron Healthcare Solutions, Inc.	2	$47
Abbott	2	$39
Scpharmaceuticals Inc.	2	$36
Sanofi	2	$36
Recordati_rare_diseases_inc.	1	$26
Novo Nordisk	1	$26
Medtronic	1	$23
Kyowa Kirin, Inc.	1	$18
Cormedix Inc.	1	$17
Verona Pharma, Inc.	1	$17
Amicus Therapeutics, Inc.	1	$15
Chiesi USA, Inc.	1	$14

How this compares

$159,414 in reported general payments places this provider in the 90th percentile of 125 nephrology providers in Nevada.

See all nephrology providers in Nevada →

Medicare billing

Part B allowed, 2024

$211,360

Medicare patients

665

Services billed

1,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Reno

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →